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DHA and arachidonic acid (AA) are important for neurodevelopment. A traditional neonatal neurological examination and the evaluation of
general movement quality are sensitive techniques for assessing neurodevelopment in young infants. Mildly abnormal general movements at
3 months have been associated with a non-optimal current brain condition. We investigated whether supplementation of DHA during pregnancy
and lactation influences the infant’s brain development and whether additional AA modulates this effect. Healthy women were randomly assigned
to DHA (220 mg/d, n 42), DHA þ AA (220 mg each/d, n 41) or control (n 36), from about week 17 (range 14–20 weeks) of pregnancy until
12 weeks postpartum. The control and the DHA þ AA groups had approximately comparable dietary DHA/AA ratios. The standardised neonatal
neurological examination was carried out at 2 weeks. General movement quality was assessed at 2 and 12 weeks. Neither DHA alone nor
DHA þ AA influenced outcomes in the traditional examination. General movement quality of infants in the DHA group was lower than that
of infants in the other two groups, especially at 12 weeks: 61 % of the infants in the DHA group showed mildly abnormal general movements
compared with 31 % in the control group (P¼0·008) and 34 % in the DHA þ AA group (P¼0·015). We conclude that general movement quality
at 12 weeks is sensitive to the maternal dietary DHA/AA balance.
DHA: Arachidonic acid: Supplementation: Pregnancy: General movements: Infant brain development
The long-chain PUFA (LCP) DHA (22 : 6n-3) and arachidonic
acid (AA; 20 : 4n-6) are structural components of membrane
phospholipids, modulators of gene expression and precursors
of eicosanoids, resolvins and (neuro)protectins(1). DHA and
EPA (20 : 5n-3) are mainly derived from fish, while meat,
poultry and eggs are the most important sources of dietary
AA. Both DHA and AA are considered important for brain
development.
Animal studies and to a lesser extent human trials with n-3
LCP in pregnant women and newborns showed that neonatal
brain DHA is positively related to cognitive and behavioural
performance and that small differences in brain DHA content
may result in subtle effects(2). However, although many
studies addressed the influence of DHA or fish oil supplemen-
tation on several aspects of brain development, the results
remain inconclusive at best(2). The high accretion rate of
AA in the fetal brain, especially in early pregnancy(3),
and the positive association between prenatal AA status and
neurodevelopment(4) suggest that not only adequate fetal
and maternal DHA, but also adequate fetal and maternal
AA status, is important. In addition, maternal LCP status is
known to decline during pregnancy(5). As far as we know,
no studies have been performed on the effects of maternal
supplemental AA or DHA þ AA during pregnancy and lacta-
tion on neurodevelopment in human subjects.
Since the effects of supplemental LCP during pregnancy
and lactation are expected to be subtle, sensitive techniques
are needed to evaluate their effects on brain development. In
the present study, we applied a traditional neurological exam-
ination(6), which yields a neurological classification and a
neurological optimality score, while we also assessed the
quality of general movements(7). The outcomes of the two
techniques have previously been shown to be sensitive to
changes in LCP status(8,9). Both techniques assess the integrity
of the young nervous system, which – in contrast to the adult
nervous system – is organised in a relatively generalised
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manner. The developmental difference in organisation
between the infant and adult brain is, for instance, the
reason why even severe impairments such as cerebral
palsy can only be initially diagnosed from 18 months on.
The traditional neurological examination summarises the
spinal cord, brainstem and cortico-subcortical function to an
equal extent, whereas the assessment of general movements
especially provides information on the integrity of cortical–
subcortical circuitries(10).
We investigated whether maternal DHA supplementation
influences early neurological outcomes and whether additional
AA modulates the effect of DHA.
Subjects and methods
Participants
The present study was part of a double-blind placebo-
controlled randomised trial in which we explored the influence
of DHA with or without AA during pregnancy and lactation
on infant neurodevelopment, maternal mood(11) and cognition,
and on the fatty acid composition of milk(12). Apparently
healthy pregnant women were recruited by midwives or
gynaecologists in and about the city of Groningen in The
Netherlands. The inclusion of participants took place from
December 2004 until December 2006. We included women
with a first or second low-risk singleton pregnancy and
excluded women with vegetarian or vegan diets and women
with diabetes mellitus. Women were enrolled between the
14th and 20th weeks of pregnancy, with the majority (80 %)
being enrolled between 15·6 and 17·4 weeks postmenstrual
age (mean 16·5 weeks). Stop criteria for participation were
delivery before 37 or after 42 weeks and any maternal or
neonatal complications. At enrolment, the women were
randomised to three groups using block randomisation.
We included 183 women in the trial, 58 of whom dropped
out before week 36 of pregnancy due to a lack of motivation
to complete the questionnaires on a regular basis and take
supplements daily (n 23 in the control group, n 20 in the
DHA group and n 15 in the DHA þ AA group). In the control
group, three mother–infant pairs were excluded because of
preterm delivery. In the DHA group, one woman was
excluded due to early labour activity. In the DHA þ AA
group, two infants were excluded, one because of preterm
birth and one because of maternal gestational diabetes
mellitus. The number of mother–infant pairs lost to follow-
up did not differ between the groups (P¼0·33). Ultimately,
119 mother–infant pairs were evaluated (control, n 36;
DHA, n 42; DHA þ AA, n 41).
Dietary intervention
All the women received a supplement of vitamins and
minerals according to the Dutch RDA. The women were
instructed to take two capsules once daily from enrolment
until 3 months after delivery. The DHA þ AA group received
220 mg DHA (Marinol D40, Lipid Nutrition B.V., Wormer-
veer, The Netherlands, a DHA-enriched purified fish oil)
and 220 mg AA (Wuhan Alking Bioengineering Co. Ltd,
Wuhan, China). The DHA group received 220 mg DHA
and one capsule containing soyabean oil (Wuhan Alking
Bioengineering Co. Ltd). The control group received two
capsules containing soyabean oil. Table 1 shows the daily
fatty acid intakes from the capsules for each of the three treat-
ment groups. The daily dosages of AA and DHA were within
the range of typical intakes for Western adults(13).
Characteristics
Prenatal and perinatal data were collected using the obstetrical
optimality score form. The form consists of seventy-four
variables describing socio-economic status, non-obstetrical con-
ditions during pregnancy, obstetrical history, diagnostic and
therapeutic measures, parturition and neonatal condition
immediately after birth. The obstetrical optimality score is
calculated from the number of items with values within a prede-
fined optimal range(14). Data on infant feeding were collected
at 2 and 12 weeks. Infant formula was not provided by the
investigators, but since at the time of the study, none of the
commercially available formulas contained DHA or AA, and
their a-linolenic acid (ALA) and linoleic acid (LA) contents
were within a narrow range, we consider all formulas equal.
Neurological examination
The infants’ neurological condition was assessed using two
instruments. A traditional and detailed neurological assess-
ment(6) was performed 2 weeks after birth (mean 14·7 d
(SD 3·9) d). This examination was used to summarise traditional
neurological findings, such as spontaneous motor behaviour,
reactions, reflexes and muscle tone regulation. Neurological
findings were described in two ways, firstly by using the
clinical classification (normal, mildly abnormal and definitely
abnormal neurological condition)(15) and secondly by using
the neurological optimality score (scored to a maximum of
60)(14). Neurological condition was also evaluated on the
basis of general movement quality. General movements are
movements involving all parts of the body, characterised by
variation and complexity. They emerge during early fetal
life and disappear at about 4 months post-term when goal-
directed movements emerge. The typical characteristics
disappear in cases of dysfunction(10). The infants’ general
movements were assessed twice: in the second postnatal
week (the ‘writhing’ phase) and in the twelfth postnatal
week (the ‘fidgety’ phase). To this end, spontaneous motility
in the supine position was videotaped for at least 5 min.
General movement quality was assessed according to
previously established methods(16). Specifically, movements
were classified as normal optimal, normal suboptimal,
mildly abnormal or definitely abnormal (Table 2). It is
important to emphasise that the label ‘mildly abnormal’
Table 1. Daily intakes of fatty acids (in mg) from the supplements
Control group DHA group DHA þ AA group
LA 535 274 46
ALA 60 32 7
AA 0 15 220
EPA 0 34 36
DHA 0 220 220
LA, linoleic acid, 18 : 2n-6; ALA, a-linolenic acid, 18 : 3n-3; AA, arachidonic acid,
20 : 4n-6; EPA, 20 : 5n-3; DHA, 22 : 6n-3.

















is a descriptor of movement quality, indicating lower move-
ment complexity and less variation. In other words, it does
not indicate a mildly abnormal brain condition. Mildly abnor-
mal general movements are within the range of ‘clinically
normal’ movements, but they reflect a non-optimal condition
of the young infant brain. The majority of typically developing
infants shows normal suboptimal general movements, and
normal optimal general movements are considered as excel-
lent movements. Normal optimal general movements occur
in only 10–20 % of 3-month-old term infants(10,17). Two
assessors (S. A. v. G. and M. H.-A.), blinded to the interven-
tion, analysed the videos together. In case of disagreement, the
findings were discussed until a consensus was reached.
Fatty acid analysis
In the 36th week of pregnancy, maternal EDTA-anticoagu-
lated blood was collected by venepuncture. The erythrocyte
fatty acid compositions were determined using our previously
described capillary GC method with flame ionisation
detection(18). The erythrocyte fatty acid compositions are
presented in relative amounts, i.e. g/100 g fatty acids (wt %)
and the DHA/AA ratio in wt/wt.
Statistical analyses
Statistics were performed with the SPSS software package,
version 16 (SPSS Inc., Chicago, IL, USA). The data were
evaluated on the basis of intention to treat. The power analysis
was based on the neurological optimality score at 2 weeks as
the primary outcome parameter. Power analysis revealed that
sixty-four infants per group were needed for the detection of a
two-point ( ¼ 0·5 SD) difference in the neurological optimality
score (power ¼ 0·85, a ¼ 0·05). We were unable to perform a
power analysis on general movement quality since the effect
of prenatal LCP supplementation on this parameter could
not be estimated from any other study. During data collection,
we noticed that the number of infants with mildly abnormal
general movements at 12 weeks greatly exceeded the numbers
found in previous studies with healthy infants (i.e. about
25–30 %)(17,19). The excess proved group specific and
subsequent disclosure of blinding revealed that this excess
occurred in the DHA-only group. In high-risk infants, the
presence of mildly abnormal general movements has been
associated with an increase in minor neurological dysfunction
at school age(7), although the prognostic value in healthy
infants is currently unknown. We decided to discontinue the
inclusion of participants. The between-group differences in
general movement quality were highly significant, indicating
that the group sizes conferred sufficient power to detect
subtle differences in neurological development. The identical
medians of the neurological optimality score indicated that
this parameter exhibited no trend towards between-group
differences.
Between-group differences in neurological optimality score,
obstetrical optimality score, maternal age, gestational age and
birth weight were calculated using a one-way ANOVA with
Bonferroni correction at P,0·05. Between-group differences
in general movement scores, percentage of women with
higher education, maternal and paternal smoking, parity and
sex were calculated using a x 2 test corrected for Bonferroni
at P,0·017 (0·05/3 for three between-group analyses).
Linear or logistic multivariate regression was applied to
correct the effect of the intervention for potential confounders,
such as maternal age, sex, gestational age at birth, birth
weight, maternal education, maternal parity, paternal and
maternal smoking and duration of breastfeeding. The DHA
and DHA þ AA groups were compared with the control
group in the ‘default’ model. New models were created
excluding the control group to compare differences between
the DHA and the DHA þ AA groups. A Kruskal–Wallis
test was performed to study the effect of supplementation on
maternal erythrocyte DHA, AA or DHA/AA; P,0·017 was
considered to be significant. To study whether maternal eryth-
rocyte DHA, AA or the DHA/AA ratio correlated with the
neurological optimality score, a Spearman correlation was
used at P,0·05. Mann–Whitney U tests were used to
calculate differences in maternal erythrocyte DHA, AA and
DHA/AA for different general movement scores (P,0·05).
Ethical statement
The present study was conducted according to the guidelines
laid down in the Declaration of Helsinki, and all procedures
involving human subjects were approved by the Central
Committee on Research Involving Human Subjects (CCMO,
the Hague, The Netherlands; protocol number P03.1071C).
All the women provided written informed consent. The trial
is registered under ISRCTN58176213.
Results
The 119 mother–infant pairs did not show any between-
group differences for the prenatal, perinatal and social
characteristics (Table 3).
Maternal erythrocyte fatty acid contents (wt %) and ratios
(wt/wt) in the 36th week of pregnancy were analysed to be
used as compliance parameters. Compared with the control
group, the erythrocyte DHA was higher after DHA
(P,0·001) and DHA þ AA (P,0·001) supplementation.
Erythrocyte AA was higher in the DHA þ AA group than in
the DHA group (P,0·001). Supplementation of DHA alone
Table 2. Classification of general movement quality and its significance to the current brain condition(7)
Complexity Variation Fluency Significance to brain condition
Normal optimal GM þþþ þþþ þ Excellent
Normal suboptimal GM þþ þþ 2 Typical
Mildly abnormal GM þ þ 2 Non-optimal
Definitely abnormal GM 2 2 2 Dysfunctional
GM, general movements.

















tended to lower erythrocyte AA (P¼0·085). The erythrocyte
DHA/AA ratio was highest in the DHA group and lowest in
the control group (P,0·001). The DHA þ AA group
showed an intermediate erythrocyte DHA/AA ratio
(DHA þ AA group compared with control group, P¼0·004;
DHA þ AA group compared with DHA group, P¼0·002;
Table 4). Supplementation also included relatively small
amounts of LA, ALA and EPA. Erythrocyte LA and ALA
did not differ between the groups. Erythrocyte EPA was
higher in mothers in the DHA group compared with the
control group (P¼0·004) and the DHA þ AA group
(P¼0·009). The control and DHA þ AA groups did not
differ in erythrocyte EPA content (P¼0·635).
The distribution of the neonatal neurological classification
in the second postnatal week and the general movement
quality in the second and twelfth weeks are shown in
Table 5. There were no between-group differences in neonatal
neurological classification. None of the infants were classified
as having a definitely abnormal neonatal neurological
condition and the rate of mild abnormality varied between
15 and 20 %. The neurological optimality score was identical
in the three treatment groups: control, median 52 (range
44–60); DHA, median 52 (46–57); DHA þ AA, median
52 (44–58), P¼0·95. Virtually none of the infants showed
normal optimal general movements, and therefore we recoded
normal optimal and normal suboptimal general movements
into normal general movements. Only one infant displayed
definitely abnormal general movements at 2 weeks (control
group) and one at 12 weeks (DHA group). We compared
normal with mildly abnormal general movements and
excluded the infants with definitely abnormal general move-
ments from statistical analyses. Combining these infants
with those with mildly abnormal general movements into an
abnormal general movements’ group did not change the
results or conclusions (data not shown). At 2 weeks, infants
in the DHA group tended to show mildly abnormal general
movements (54 %) more frequently than the infants in the con-
trol group (36 %, P¼0·13) and the DHA þ AA group (40 %,
P¼0·21; no difference between control and DHA þ AA,
P¼0·73). Between-group differences were more pronounced
Table 4. Fatty acids (wt %) in maternal red blood cells in the 36th week of pregnancy
(Median values with their ranges)
Control group (n 37) DHA group (n 41) DHA þ AA group (n 37)
Median Range Median Range Median Range
LA 8·65 6·19–10·48 7·95 5·92–10·23 8·06 5·98–13·10
ALA 0·19 0·08–0·32 0·19 0·10–0·34 0·18 0·09–0·33
AA 12·91 9·95–14·95 12·13 9·63–15·22 13·60 11·17–15·52 c
EPA 0·31 0·16–0·56 0·38 0·19–1·31 0·31 0·16–0·87 a,c
DHA 4·44 3·00–6·92 5·51 3·98–8·20 5·57 2·48–8·32 a,b
DHA/AA 0·34 0·24–0·70 0·46 0·34–0·75 0·41 0·19–0·69 a,b,c
LA, linoleic acid; ALA, a-linolenic acid; AA, arachidonic acid.
a Significant difference between control group and DHA group.
b Significant difference between control group and DHA þ AA group.
c Significant difference between DHA and DHA þ AA groups; P,0·017.
Table 3. Prenatal, perinatal and social characteristics of the 119 mother–infant pairs included in the study







Mean SD Mean SD Mean SD P
Maternal age (years) 32·4 5·1 32·5 4·4 32·7 4·8 0·96
Gestational age at birth (weeks) 40·2 1·0 40·2 1·1 40·2 1·1 0·99
Birth weight (g) 3565 547 3585 462 3644 373 0·74
OOS 64·3 3·8 63·8 4·0 63·4 3·8 0·64
n % n % n % P
Maternal higher education* 27 77 30 71 27 66 0·21
Maternal smoking during pregnancy 2 6 2 5 3 7 0·88
Paternal smoking during pregnancy 10 29 9 21 10 24 0·72
First born 21 60 25 60 19 46 0·38
Male sex 22 63 16 38 19 46 0·091
Exclusively formula fed† 5 14 2 5 6 15 0·28
Exclusively breastfed after 2 weeks 29 81 36 86 33 81 0·78
Exclusively formula fed after 12 weeks 21 58 28 67 23 56 0·59
AA, arachidonic acid; OOS, obstetrical optimality score.
* At least high school completed.
† Infant formula was not provided by the investigators. None of the commercially available formulas contained DHA or AA at
the time the study took place.

















at 12 weeks: 61 % of the infants in the DHA group showed
mildly abnormal general movements compared with 31 % in
the control group (P¼0·008) and 34 % in the DHA þ AA
group (P¼0·015; no difference between control and
DHA þ AA, P¼0·74). Multivariate analyses took into
account the role of confounders, namely maternal age at
inclusion, sex, gestational age at birth, birth weight, maternal
education, parity, paternal and maternal smoking and duration
of breastfeeding. The neurological optimality scores and
neonatal neurological classifications did not differ between
the three groups. General movement quality at 2 weeks
was significantly lower in the DHA group when compared
with the control group. At 12 weeks, infants in the DHA
group showed a higher rate of mildly abnormal general
movements than those in the control group and DHA þ AA
group (Table 6).
There were no significant correlations between maternal
erythrocyte LA, ALA, AA, EPA, DHA or the DHA/AA
ratio and the neurological optimality score. Mann–Whitney
U tests revealed that mothers of infants with mildly abnormal
general movements at 2 weeks had lower erythrocyte AA
(median 12·25; range 9·63–14·92) compared with those of
infants with normal general movements (13·03 (9·95–15·52),
P¼0·022). General movement quality at 12 weeks did not
relate to maternal erythrocyte LA, ALA, AA, EPA, DHA or
the DHA/AA ratio.
Discussion
The present study indicates that supplementation with DHA
alone, but not DHA þ AA, is associated with a higher rate
of mildly abnormal general movements. The traditional neuro-
logical examination did not reveal between-group differences
in neonatal neurological classification or neurological optimal-
ity scores. We realise that the study lacks the power to permit
the conclusion that supplementation with DHA alone or with
DHA þ AA does not affect neurological optimality scores.
However, the finding that the median values of the neuro-
logical optimality score were identical in the three groups
suggests that increasing the number of participants would
not lead to a different conclusion.
Table 5. Distribution of neurological classification in the second postnatal week and general movement quality in the second and twelfth postnatal
weeks in the three treatment groups
NNC GM2 GM12
N MA DA NA NO NS MA DA NA NO NS MA DA
Control (n 36) 28 7 0 1 a 1 19 11 1 4 a 2 23 11 0 a
DHA (n 42) 35 6 0 1 a 0 17 20 0 5 a 0 16 25 1 b
DHA þ AA (n 41) 33 8 0 0 a 1 22 15 0 3 a 1 26 14 0 a
NNC, neonatal neurological classification at 2 weeks; GM2, general movements at 2 weeks; GM12, general movements at 12 weeks; N, normal; MA, mildly abnormal; DA, defi-
nitely abnormal; NO, normal optimal; NS, normal suboptimal; NA, not assessed, as the children were not in the appropriate behavioural state and NNC or GM quality could
not be assessed; AA, arachidonic acid.
There were no between-group differences for NNC and GM2.
a Identical superscripts indicate that there are no significant differences between treatment groups.
b Significantly different from control (P¼0·008) and DHA þ AA (P¼0·015).
Table 6. Effects of intervention after correction for potential confounders
Coefficient B 95% CI P Explained variance r 2*
NOS 8·6%
Control v. DHA 0·022 21·266, 1·534 0·85
Control v. DHA þ AA 0·003 21·398, 1·440 0·98
DHA v. DHA þ AA 20·012 21·454, 1·315 0·92
Exp B 95% CI P Nagelkerke r 2 (%); x 2; P*
MA NNC 27·5; 21·0; 0·050
Control v. DHA 0·814 0·208, 3·184 0·77
Control v. DHAþAA 1·141 0·295, 4·409 0·85
DHA v. DHA þ AA 1·589 0·427, 5·908 0·49
MA GM at 2 weeks 14·2; 11·3; 0·51
Control v. DHA 3·867 1·228, 12·173 0·021
Control v. DHA þ AA 1·854 0·585, 5·880 0·29
DHA v. DHA þ AA 0·511 0·188, 1·390 0·19
MA GM at 12 weeks 30·4; 28·7; 0·004
Control v. DHA 4·121 1·335, 12·719 0·014
Control v. DHA þ AA 1·162 0·366, 3·686 0·80
DHA v. DHA þ AA 0·264 0·089, 0·788 0·017
NOS, neurological optimality score; AA, arachidonic acid; MA, mildly abnormal; NNC, neonatal neurological classifi-
cation; GM, general movements.
* The explained variance is assessed in the models in which both the DHA and DHA þ AA groups are compared with
the control group. To compare the DHA group with the DHA þ AA group, a new model was created from which the
control group was excluded. The first mentioned group functions as the reference group (i.e. ¼ 0). The effects of
the intervention are corrected for maternal age (at inclusion), sex, gestational age at birth, birth weight, maternal
education, parity, paternal and maternal smoking and duration of breastfeeding.

















We used general movement quality as a parameter for
neurodevelopment, since it proved sensitive to postnatal
LCP supplementation in term infants in a previous study(19).
In the present study, we found more mildly abnormal general
movements after supplementation of DHA alone, whereas
general movement quality after supplementation of
DHA þ AA was comparable to that in the control group.
The latter suggests that the addition of AA neutralised the
effect of DHA. DHA þ AA did not influence general move-
ment quality compared with the control group. The label
mildly abnormal is a descriptor of movement quality, indicat-
ing lower movement complexity and less variation (Table 2).
It indicates non-optimal rather than mildly abnormal current
brain condition. Although there is no information on low-
risk populations, the presence of mildly abnormal general
movements in high-risk populations is associated with an
increased prevalence of minor neurological dysfunction and
behavioural problems at school age. The presence of mildly
abnormal general movements, however, cannot be used as a
single predictor of later outcome. Nevertheless, accumulating
evidence indicates that the degree of variability in motor
behaviour is a marker of the functional integrity of the devel-
oping nervous system, in particular of the integrity of cerebral
connectivity, i.e. white matter function(10,20).
Generally, DHA status is positively associated with neuro-
logical development. We supplemented a relatively low dose
of DHA. Maternal DHA supplementation studies during
pregnancy or during pregnancy and subsequent lactation
with doses ranging from 200 to 3300 mg DHA/d resulted in
improved visual acuity at 4 months(21), enhanced problem
solving at 9 months(22), improved eye and hand coordination
at 2·5 years(23) and a higher IQ at 4 years(24), whereas other
developmental parameters showed no benefit(4). Since the
reported beneficial effects of DHA do not seem dose
dependent or duration dependent (supplementation during
pregnancy or during pregnancy and subsequent lactation)
and the effects are mainly found in older infants and toddlers,
it is conceivable that the positive effects of DHA on cognition
first become expressed after early infancy. Furthermore, the
relationship between DHA intake and neurological develop-
ment may be non-linear, for which there is some evidence
from animal studies(25,26,27). Negative associations between
fish intake during pregnancy and fetal growth(28,29,30) have
been shown.
Bouwstra et al. (9) reported that general movement quality is
associated with prenatal AA status rather than prenatal DHA
status. In the present study, the effect of supplemental DHA
was neutralised by additional AA, while supplementation
of DHA alone tended to lower maternal AA status. These
observations could indicate that the effect of DHA supplemen-
tation on general movement quality is related to the lower
maternal AA status.
The average daily intakes of DHA and AA in The Nether-
lands are estimated to amount to 100 mg/d each. Accordingly,
he average fish intake in the present study population amounts
to 0·94 meals per week, of which 0·45 meals include fatty
fish(11). Consequently, supplementation of 220 mg DHA
increased the dietary DHA/AA ratio, while this ratio became
largely restored by the additional supplementation of 220 mg
AA in the DHA þ AA group. The similarities between the
dietary DHA/AA ratios of the control and DHA þ AA
groups were reflected by a similarly low percentage of
mildly abnormal general movements, while the higher dietary
DHA/AA ratio of the DHA group proved causally related to a
substantially increased occurrence of mildly abnormal general
movements (Table 4). The estimated dietary DHA/AA
ratios of the three groups were, however, not fully reflected
by the corresponding erythrocyte DHA/AA ratios, since here
the DHA þ AA group occupied a position intermediate
to the control and DHA groups (Table 6). This apparent
discrepancy between the dietary and erythrocyte DHA/AA
ratios suggests that it is the maternal dietary DHA/AA ratio
rather than the widely employed erythrocyte DHA/AA
status, which is implicated in the occurrence of mildly abnor-
mal general movements.
Various brain regions in neonatal baboons differ in DHA,
AA and consequently the DHA/AA ratio(31). This may
imply region-specific regulation of brain LCP contents, for
instance by fatty acid-binding proteins(32) and other as yet
poorly understood mechanisms. Grey matter contains high
amounts of DHA and AA in contrast to white matter(31). It
can be surmised that white matter LCP contents may be less
well regulated and consequently be more sensitive to DHA
or AA changes than other brain regions. Since DHA and
AA are known to compete for incorporation in the
brain(33,34), supplementation of DHA may lead to a decrease
in AA, especially in white matter, whereas additional AA
supplementation restores the DHA/AA balance. In addition,
white matter shows a low DHA/AA ratio, i.e. more AA than
DHA, when it is compared with grey matter. Since general
movement quality is associated with the integrity of the
white matter(10,20), this could explain why general movement
quality is sensitive to the dietary DHA/AA ratio.
DHA depletion is undoubtedly associated with altered brain
function(27). Although the current Western diet is considered
to be at least marginal in DHA, results from DHA supplemen-
tation studies remain inconclusive(2,35). We hypothesise that
various brain regions differ in LCP contents due to differences
in regulation. It should be realised that different neurodevelop-
mental tests subserve the evaluation of different brain
functions. In addition, it is likely that brain regions and
functions exhibit different sensitivities to changes in LCP
status. For example, Dunstan et al. (23) showed a beneficial
effect on eye and hand coordination, but not on other
subscales of the Griffith Mental Developmental Scales, the
Peabody Picture Vocabulary Test, or the Child Behaviour
Checklist. Maternal fish oil supplementation during 4
months of lactation did not affect problem-solving ability at
9 months of age, but at 1 year and 2 years, the fish oil
group performed less well on the MacArthur Communicative
Developmental Inventory, especially the boys(36). The various
risk factors exhibit different dose responses to LCP n-3 in
CVD as well(37). Differences in sensitivity may in part explain
why the use of various tests at various ages led to different
results and conclusions regarding the effects of LCP
supplementation on developmental outcome.
We conclude that general movement quality is sensitive
to maternal dietary DHA/AA balance during pregnancy and
lactation. Supplementation of DHA without AA caused an
increase in mildly abnormal general movements in early
infancy, which in high-risk infants has been associated with
a non-optimal brain condition. However, the prognostic

















significance of a non-optimal brain condition in healthy term
infants is currently unknown. Therefore, our data stress the
need for a long-term follow-up with sensitive and function-
specific instruments in studies evaluating the effect of early
LCP supplementation on neurodevelopmental outcome.
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